Corrigendum to ‘B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis’ [J Hepatol (2022) doi: 10.1016/j.jhepr.2022.100460]
Maaike Biewenga,
Sebastiaan Heidt,
Manon Vergunst,
Camiel J.M. Marijnissen,
Rob A. de Man,
Annemiek A. van der Eijk,
Adriaan J. van der Meer,
Leendert A. Trouw,
Bart van Hoek
Affiliations
Maaike Biewenga
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
Sebastiaan Heidt
Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands
Manon Vergunst
Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands
Camiel J.M. Marijnissen
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
Rob A. de Man
Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
Annemiek A. van der Eijk
Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
Adriaan J. van der Meer
Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
Leendert A. Trouw
Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands
Bart van Hoek
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands; Corresponding author. Address: Department of Gastroenterology and Hepatology, C4-P, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Tel.: +31-71-526-1852; Fax: +31-71-524-8115.
